Nello Mainolfi

CIK: 0001821189

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)28 (65.1%)

Position reduction

Option Exercises (M)13 (30.2%)

Derivative conversions

Awards (A)2 (4.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KYMR

Kymera Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (43 total)

KYMR
Kymera Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
262 shares at avg. $116.12$30K
KYMR
Kymera Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
7.6K shares at avg. $114.43$870K
KYMR
Kymera Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
4.9K shares at avg. $113.24$552K
KYMR
Kymera Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
5.5K shares at avg. $112.42$619K
KYMR
Kymera Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
3.5K shares at avg. $111.44$393K
KYMR
Kymera Therapeutics, Inc.
Oct 1, 2026
Exercise(M)
Direct
30K shares at avg. $2.08$62K
KYMR
Kymera Therapeutics, Inc.
Oct 1, 2026
Sale(S)
Direct
8.2K shares at avg. $115.40$950K
KYMR
Kymera Therapeutics, Inc.
Jul 7, 2026
Sale(S)
Direct
50K shares at avg. $119.00$6.0M
KYMR
Kymera Therapeutics, Inc.
Jul 7, 2026
Exercise(M)
Direct
50K shares at avg. $2.08$104K
KYMR
Kymera Therapeutics, Inc.
Jul 1, 2026
Exercise(M)
Direct
80K shares at avg. $2.08$166K
KYMR
Kymera Therapeutics, Inc.
Jul 1, 2026
Sale(S)
Direct
3.3K shares at avg. $116.56$389K
KYMR
Kymera Therapeutics, Inc.
Jul 1, 2026
Sale(S)
Direct
44.1K shares at avg. $115.69$5.1M
KYMR
Kymera Therapeutics, Inc.
Jul 1, 2026
Sale(S)
Direct
6.6K shares at avg. $113.98$755K
KYMR
Kymera Therapeutics, Inc.
Jul 1, 2026
Sale(S)
Direct
24.1K shares at avg. $114.96$2.8M
KYMR
Kymera Therapeutics, Inc.
Jul 1, 2026
Sale(S)
Direct
1.9K shares at avg. $112.80$212K
KYMR
Kymera Therapeutics, Inc.
Apr 29, 2026
Sale(S)
Direct
12.1K shares at avg. $81.70$985K
KYMR
Kymera Therapeutics, Inc.
Apr 29, 2026
Exercise(M)
Direct
30K shares at avg. $2.08$62K
KYMR
Kymera Therapeutics, Inc.
Apr 29, 2026
Sale(S)
Direct
17K shares at avg. $80.74$1.4M
KYMR
Kymera Therapeutics, Inc.
Apr 29, 2026
Sale(S)
Direct
936 shares at avg. $82.45$77K
KYMR
Kymera Therapeutics, Inc.
Mar 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
215K shares-
KYMR
Kymera Therapeutics, Inc.
Feb 25, 2026
Sale(S)
Direct
19.8K shares at avg. $89.78$1.8M
KYMR
Kymera Therapeutics, Inc.
Feb 25, 2026
Sale(S)
Direct
8 shares at avg. $93.49$747.92
KYMR
Kymera Therapeutics, Inc.
Feb 25, 2026
Sale(S)
Direct
1.5K shares at avg. $92.81$139K
KYMR
Kymera Therapeutics, Inc.
Feb 25, 2026
Sale(S)
Direct
3.3K shares at avg. $91.76$302K
KYMR
Kymera Therapeutics, Inc.
Feb 25, 2026
Sale(S)
Direct
5.4K shares at avg. $90.39$491K

		Type	Shares	Price		Ownership
Oct 1, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	262	$116.12	$30,423	Direct
Oct 1, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	7,601	$114.43	$869,782	Direct
Oct 1, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	4,876	$113.24	$552,158	Direct
Oct 1, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	5,506	$112.42	$618,985	Direct
Oct 1, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	3,525	$111.44	$392,826	Direct
Oct 1, 2026	KYMR Kymera Therapeutics, Inc.	Exercise(M)	30,000	$2.08	$62,400	Direct
Oct 1, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	8,230	$115.40	$949,742	Direct
Jul 7, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	50,000	$119.00	$5,950,000	Direct
Jul 7, 2026	KYMR Kymera Therapeutics, Inc.	Exercise(M)	50,000	$2.08	$104,000	Direct
Jul 1, 2026	KYMR Kymera Therapeutics, Inc.	Exercise(M)	80,000	$2.08	$166,400	Direct
Jul 1, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	3,336	$116.56	$388,841	Direct
Jul 1, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	44,050	$115.69	$5,096,070	Direct
Jul 1, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	6,626	$113.98	$755,204	Direct
Jul 1, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	24,105	$114.96	$2,771,002	Direct
Jul 1, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	1,883	$112.80	$212,411	Direct
Apr 29, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	12,059	$81.70	$985,220	Direct
Apr 29, 2026	KYMR Kymera Therapeutics, Inc.	Exercise(M)	30,000	$2.08	$62,400	Direct
Apr 29, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	17,005	$80.74	$1,372,984	Direct
Apr 29, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	936	$82.45	$77,173	Direct
Mar 2, 2026	KYMR Kymera Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	215,000	-	-	Direct
Feb 25, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	19,764	$89.78	$1,774,412	Direct
Feb 25, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	8	$93.49	$748	Direct
Feb 25, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	1,501	$92.81	$139,308	Direct
Feb 25, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	3,293	$91.76	$302,166	Direct
Feb 25, 2026	KYMR Kymera Therapeutics, Inc.	Sale(S)	5,434	$90.39	$491,179	Direct

1-25 of 43 transactions

About Mainolfi Nello

Mainolfi Nello (SEC CIK 0001821189) files insider reports with the SEC as Chief Executive Officer of Kymera Therapeutics, Inc. (KYMR).

Signal8 holds 15 ownership filings by Mainolfi Nello, all Form 4s, filed between Jan 13, 2025 and Oct 1, 2026. Those filings report 43 transactions, from Jan 10, 2025 to Oct 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Mainolfi Nello's filings is in WATERTOWN, MA.

Recent filings by Mainolfi Nello

Oct 1, 2026: Open-market sales of KYMR shares (5 lines, Form 4, code S).
Oct 1, 2026: Option exercise of KYMR shares (Form 4, code M).
Oct 1, 2026: Open-market sale of KYMR shares (Form 4, code S).
Jul 7, 2026: Open-market sale of KYMR shares (Form 4, code S).
Jul 7, 2026: Option exercise of KYMR shares (Form 4, code M).

Other insiders filing for Kymera Therapeutics, Inc. (KYMR)

Adams Brian, Chief Legal Officer
Rooney Terence, Chief Medical Officer
Jacobs Bruce N., Chief Financial Officer
Goodman Noah, Chief Business Officer
Booth Bruce, Director
BVF PARTNERS L P/IL, Director

How to read Form 4 transaction codes